MAIA Biotechnology, Inc.
DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
MAIA Biotechnology, Inc. (NYSE American: MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for ateganosine in third-line non-small cell lung cancer (NSCLC). The trial is funded by a $2.3 million NIH grant. Ateganosine has FDA Fast Track designation and showed promising overall survival data in prior trials.
On September 15, 2026, 162 insider stock purchases were reported. Notable transactions include Cascade Investment buying 176,547 shares of Republic Services (RSG) for $39.4M, Tricor PMT25 Holdings buying 525,000 shares of CPI Card Group (PMTS) for $11.3M, and Devon Energy (DVN) CEO buying 3,913 shares for $199,876.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MAIA (MAIA Biotechnology, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent MAIA coverage spans insider activity, corporate actions and technology.
In the last 30 days, MAIA insiders filed 6 SEC Form 4 transactions — 6 purchases ($336K) and no sales. The most active reporter was Guerrero Ramiro with 5 filings.
First U.S. patient dosing marks trial progression and may unlock further funding.
Positive milestone may boost stock on expectations of efficacy data and potential accelerated approval.
Executive buying signals confidence in upcoming biotech milestones.
Insider purchase signals confidence, may support short-term price upside.
Small insider purchase may signal confidence but limited price impact.
AlphAI scores every news story that mentions MAIA with an AI model for sentiment and relevance, and aggregates insider trades from MAIA Biotechnology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.
3 min readMAIA Biotechnology, Inc. (NYSE American: MAIA) dosed the first U.S. patient in its Phase 2 THIO-101 trial for ateganosine in third-line non-small cell lung cancer (NSCLC). The trial is funded by a $2.3 million NIH grant. Ateganosine has FDA Fast Track designation and showed promising overall survival data in prior trials.
2 min readOn September 15, 2026, 162 insider stock purchases were reported. Notable transactions include Cascade Investment buying 176,547 shares of Republic Services (RSG) for $39.4M, Tricor PMT25 Holdings buying 525,000 shares of CPI Card Group (PMTS) for $11.3M, and Devon Energy (DVN) CEO buying 3,913 shares for $199,876.
2 min readVitoc Vlad (Chief Executive Officer) purchased 73,000 shares of MAIA Biotechnology, Inc. (MAIA) at $1.37 ($0.10M total) on 2026-09-14.
1 min readGuerrero Ramiro purchased 37,595 shares of MAIA Biotechnology, Inc. (MAIA) at $1.32 on 2026-09-10.
1 min readUniverse Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
2 min readGuerrero Ramiro purchased 133,790 shares of MAIA Biotechnology, Inc. (MAIA) at an average of $1.38 ($1.35–$1.39, $0.18M total) across 3 trades over 2026-08-26 to 2026-08-28.
1 min readGuerrero Ramiro purchased 1,794 shares of MAIA Biotechnology, Inc. (MAIA) at $1.33 on 2026-08-24.
1 min readGuerrero Ramiro purchased 11,899 shares of MAIA Biotechnology, Inc. (MAIA) at $1.37 on 2026-08-20.
1 min readMAIA Biotechnology (NYSE American: MAIA) reported initial Phase 2 THIO-101 Part C data in third-line advanced NSCLC. Ateganosine followed by cemiplimab (Libtayo) produced a 90.5% disease control rate (19/21) in 3L patients, compared with 25-35% for standard chemotherapy. MAIA said safety is acceptable and enrollment is completed internationally.
2 min read
